# Erythrocyte DHA/EPA Ratio Surpasses Its Individual Fatty Acid Levels in Predicting Metabolic Syndrome in Chinese Adults: A Prospective Study

**Authors:** Pinning Feng, Yan Yan, Hanzu Chen, Dongmei Ru, Xinyue Wang, Yuming Chen

PMC · DOI: 10.3390/nu17061096 · 2025-03-20

## TL;DR

This study finds that the ratio of two fatty acids in red blood cells is a better predictor of metabolic syndrome than the individual levels of those fatty acids in Chinese adults.

## Contribution

The study introduces the DHA/EPA ratio in erythrocytes as a novel predictor of metabolic syndrome prevalence and risk.

## Key findings

- Higher DHA/EPA ratios were associated with lower odds of metabolic syndrome prevalence.
- The DHA/EPA ratio was inversely linked to the incidence of metabolic syndrome over 12 years.
- EPA levels alone showed a weaker association with metabolic syndrome compared to the DHA/EPA ratio.

## Abstract

Background: The individual roles of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in mitigating metabolic syndrome (MetS) have been well-documented. However, the significance of their ratio (DHA/EPA) in erythrocytes concerning MetS remains underexplored. This study evaluated the association between the DHA/EPA ratio and MetS including its separate components. Methods: This community-based prospective cohort study involved 3497 participants aged 40 to 75 years enrolled in the Guangzhou Nutrition and Health Study (GNHS) from 2008 to 2013 in China. Baseline erythrocyte fatty acids were quantified using gas chromatography. Over a 12-year follow-up, MetS status was reassessed triennially, identifying 766 new MetS cases among the 2111 participants initially free of the syndrome. The study examined both cross-sectional and prospective relationships of EPA, DHA, and the DHA/EPA ratio with both the presence and incidence of MetS alongside its individual components. Results: Multivariable cross-sectional analyses revealed that the odds ratios (ORs) and 95% confidence intervals (CIs) for MetS prevalence in quartile 4 (vs. 1) were 1.32 (1.07, 1.62) for EPA, 0.52 (0.40, 0.66) for DHA, and 0.66 (0.52, 0.83) for the DHA/EPA ratio (all P-trend < 0.05). Analogous patterns were observed for associations with hyperlipidemia, hypertension, and hyperglycemia. In the prospective analysis, higher DHA/EPA ratios and lower EPA levels were associated with reduced 12-year incidence of MetS and hyperglycemia. Hazard ratios (HRs) and 95% CIs for MetS, comparing the extreme quartiles, were 1.26 (1.02, 1.55) for EPA and 0.75 (0.60, 0.94) for the DHA/EPA ratio. Additionally, DHA was inversely associated with the incidence of hypertension. Conclusions: The study highlights a consistent inverse relationship between the DHA/EPA ratio and both the prevalence and risk of MetS. These findings underscore the potential utility of the DHA/EPA ratio as a predictive marker or therapeutic target in MetS management.

## Linked entities

- **Chemicals:** docosahexaenoic acid (PubChem CID 445580), eicosapentaenoic acid (PubChem CID 5282847)
- **Diseases:** metabolic syndrome (MONDO:0000816), hyperlipidemia (MONDO:0021187), hyperglycemia (MONDO:0002909)

## Full-text entities

- **Diseases:** hyperlipidemia (MESH:D006949), hyperglycemia (MESH:D006943), hypertension (MESH:D006973), MetS (MESH:D024821)
- **Chemicals:** DHA (MESH:D004281), EPA (MESH:D015118), Fatty Acid (MESH:D005227)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11944844/full.md

---
Source: https://tomesphere.com/paper/PMC11944844